BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 6, 2013
View Archived Issues
Chemokine receptor modulators reported by AstraZeneca
Read More
Neuroprotective glutathione analogues discovered at University of Minnesota
Read More
Lundbeck presents new nAChR positive allosteric modulators
Read More
Knockout model casts doubt on the role of protein kinase M zeta type in memory
Read More
AstraZeneca presents overview of pipeline with 2012 results
Read More
Kyowa Hakko Kirin reviews highlights of 2012
Read More
ALK5 and/or ALK4 inhibitors developed at SK Chemicals
Read More
Merck & Co. presents new FIXa inhibitors
Read More
Sunshine Lake Pharma develops new agents for HCV infection
Read More
Pfizer begins phase I trial of anti-IgE vaccine using Cytos' VLP technology
Read More
Stem Cell Therapeutics and Trillium Therapeutics set to merge
Read More
Ono Pharmaceutical updates progress of third quarter of fiscal 2012
Read More
Biocancell reports data from phase IIb pancreatic cancer study
Read More
Antitrypanosomal reduces experimental pulmonary hypertension and pulmonary fibrosis
Read More
AOD-9604 shows promise in rabbit model of osteoarthritis
Read More
Verastem to evaluate VS-6063 plus paclitaxel in ovarian cancer
Read More
Nektar begins phase II trial of NKTR-102 in non-small cell lung cancer
Read More
RepliCel set to meet with German competent authority for hair cell product trial
Read More
GE Healthcare highlights recently launched technologies targeting cancer
Read More
MVA-85A tuberculosis vaccine well tolerated but not significantly effective in phase IIb trial
Read More
EMA approves label extension for Abilify
Read More
Merck Serono and Opexa Therapeutics enter MS drug agreement
Read More
Agreement entered into on phase II trial of universal factor Xa inhibitor antidote PRT-4445
Read More
Xenon receives Glybera approval milestone payment
Read More
ALK-1 signaling inhibitor dalantercept begins two new phase II trials
Read More